Drug, across the briefings

Atezolizumab across 18 cancers

Atezolizumab appears in 18 of the briefings; its FDA label names 5 of those diseases.

Disease	FDA label	Open Targets stage, on which gene	Trials	Active
Bladder cancer	label names disease	phase 4 on CD274	50	21
Hepatocellular carcinoma	label names disease		—	—
Lung cancer	label names disease	phase 4 on CD274	155	62
Melanoma	label names disease		—	—
Small cell lung cancer	label names disease	phase 4 on CD274	79	43
Anal cancer		phase 4 on CD274	8	3
Cervical cancer		phase 4 on CD274	30	9
Cholangiocarcinoma		phase 4 on CD274	15	7
Cutaneous squamous cell carcinoma		phase 4 on CD274	7	3
Esophageal cancer		phase 4 on CD274	24	7
Gastric cancer		phase 4 on CD274	33	11
Head and neck cancer		phase 4 on CD274	49	16
Hodgkin lymphoma		phase 4 on CD274	4	1
Kidney cancer		phase 4 on CD274	35	12
Merkel cell carcinoma		phase 4 on CD274	14	4
Mesothelioma		phase 4 on CD274	14	7
Nasopharyngeal carcinoma		phase 4 on CD274	2	2
Vulvar cancer		phase 4 on CD274	4	2

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.